Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors

Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a 1st-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors